Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRA | P10827 | 19/20 | 0.60 |
| ▸ | THRB | P10828 | 19/20 | 0.60 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.60 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.60 |
| ▸ | UGT1A1 | P22309 | 1/20 | 0.43 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.43 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23168718 | 1.00 | THRA (0.60) | THRATHRBCYP2C9CYP2C8UGT1A1 | |
| SCHEMBL23168724 | 1.00 | THRA (0.60) | THRATHRBCYP2C9CYP2C8UGT1A1 | |
| SCHEMBL23168717 | 0.90 | THRA (0.65) | THRATHRBCYP2C9CYP2C8UGT1A1 | |
| SCHEMBL23168767 | 0.85 | THRA (0.58) | THRATHRBCYP2C9CYP2C8UGT1A1 | |
| SCHEMBL23168720 | 0.82 | THRA (0.55) | THRATHRBCYP2C9CYP2C8UGT1A1 | |
| SCHEMBL23168964 | 0.82 | THRA (0.61) | THRATHRBCYP2C9CYP2C8UGT1A1 | |
| SCHEMBL24032177 | 0.81 | THRA (0.79) | THRATHRBCYP2C9CYP2C8UGT1A1 | |
| SCHEMBL23168801 | 0.80 | THRA (0.59) | THRATHRBCYP2C9CYP2C8UGT1A1 | |
| SCHEMBL23168796 | 0.80 | THRA (0.57) | THRATHRBCYP2C9CYP2C8UGT1A1 | |
| SCHEMBL23168800 | 0.79 | THRA (0.58) | THRATHRBCYP2C9CYP2C8UGT1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220411400-A1 | CHEMICAL COMPOUND AS THYROID HORMONE BETA RECEPTOR AGONIST AND USE THEREOF | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2022-12-29 | — | — | US | disclosed |
| WO-2021057791-A1 | CHEMICAL COMPOUND AS THYROID HORMONE BETA RECEPTOR AGONIST AND USE THEREOF | 广东东阳光药业有限公司 | 2021-04-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220411400-A1 | CHEMICAL COMPOUND AS THYROID HORMONE BETA RECEPTOR AGONIST AND USE THEREOF | THRB, TSHR, THRA | THRA 3/4885THRB 1/4885CYP2C9 799/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.